Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 121,535 shares, a decrease of 35.7% from the March 15th total of 188,899 shares. Based on an average daily trading volume, of 214,716 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.4% of the company’s shares are short sold.

VYNE Therapeutics Stock Down 0.3%

VYNE stock opened at $0.62 on Wednesday. The business has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.50. The company has a market cap of $20.76 million, a price-to-earnings ratio of -0.80 and a beta of 1.94. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $1.99.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Friday, February 27th. The company reported ($0.15) EPS for the quarter. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.The business had revenue of $0.13 million for the quarter. On average, equities research analysts anticipate that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VYNE. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen raised VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 2nd. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $4.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VYNE. Jane Street Group LLC bought a new position in shares of VYNE Therapeutics during the 2nd quarter worth approximately $206,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of VYNE Therapeutics by 87.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after acquiring an additional 300,000 shares during the period. Boothbay Fund Management LLC bought a new position in shares of VYNE Therapeutics during the 2nd quarter worth approximately $176,000. Two Sigma Investments LP bought a new position in shares of VYNE Therapeutics during the 3rd quarter worth approximately $74,000. Finally, Shay Capital LLC bought a new position in shares of VYNE Therapeutics during the 3rd quarter worth approximately $165,000. 83.78% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.